Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managin...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Giorgio Walter Canonica, Francesco Blasi, Pierluigi Paggiaro, Gianenrico Senna, Giovanni Passalacqua, Antonio Spanevello, Stefano Aliberti, Diego Bagnasco, Marco Bonavia, Matteo Bonini, Luisa Brussino, Caterina Bucca, Maria F. Caiaffa, Cecilia Calabrese, Gianna Camiciottoli, Marco Caminati, Giovanna E. Carpagnano, Cristiano Caruso, Stefano Centanni, Maria E. Conte, Angelo G. Corsico, Lorenzo Cosmi, Maria T. Costantino, Nunzio Crimi, Simona D’Alò, Maria D'Amato, Stefano Del Giacco, Alessandro Farsi, Elisabetta Favero, Maria P. Foschino Barbaro, Gabriella Guarnieri, Giuseppe Guida, Manuela Latorre, Salvatore Lo Cicero, Carlo Lombardi, Luigi Macchia, Francesco Mazza, Francesco Menzella, Manlio Milanese, Marcello Montagni, Paolo Montuschi, Eleonora Nucera, Roberta Parente, Vincenzo Patella, Girolamo Pelaia, Laura Pini, Francesca Puggioni, Luisa Ricciardi, Fabio L.M. Ricciardolo, Luca Richeldi, Erminia Ridolo, Giovanni Rolla, Pierachille Santus, Nicola Scichilone, Giuseppe Spadaro, Andrea Vianello, Vittorio Viviano, Mona R. Yacoub, Maria C. Zappa, Enrico Heffler
Μορφή:	Άρθρο
Γλώσσα:	English
Έκδοση:	Elsevier 2020-10-01
Σειρά:	World Allergy Organization Journal
Θέματα:	Severe asthma Biologics Oral corticosteroids Real-life Registr
Διαθέσιμο Online:	http://www.sciencedirect.com/science/article/pii/S1939455120303677

Παρόμοια τεκμήρια

Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey
ανά: Claudia Crimi, κ.ά.
Έκδοση: (2023-11-01)

Nasal polyps impact in severe asthma patients: evidences from the SANI
ανά: Giorgio Walter Canonica, κ.ά.
Έκδοση: (2020-08-01)

Economic impact of a more extensive use of FENO testing on the Italian population with asthma
ανά: Carla Rognoni, κ.ά.
Έκδοση: (2023-06-01)

Asthma severity: the patient’s point of view
ανά: Gabriella Guarnieri, κ.ά.
Έκδοση: (2024-12-01)

Is Bronchiectasis (BE) Properly Investigated in Patients with Severe Asthma? A Real-Life Report from Eight Italian Centers
ανά: Giovanna Elisiana Carpagnano, κ.ά.
Έκδοση: (2023-10-01)

Clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthma
ανά: Diego Bagnasco, κ.ά.
Έκδοση: (2020-08-01)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life
ανά: Diego Bagnasco, κ.ά.
Έκδοση: (2021-02-01)

Severe asthma: One disease and multiple definitions
ανά: Diego Bagnasco, MD, PhD, κ.ά.
Έκδοση: (2021-11-01)

Critical evaluation of asthma biomarkers in clinical practice
ανά: Giuseppe Guida, κ.ά.
Έκδοση: (2022-10-01)

Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center
ανά: Paolo Solidoro, κ.ά.
Έκδοση: (2022-01-01)

Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort
ανά: Marco Caminati, MD, κ.ά.
Έκδοση: (2024-08-01)

Phenotype overlap in the natural history of asthma
ανά: Fabio L.M. Ricciardolo, κ.ά.
Έκδοση: (2023-05-01)

Minimal clinically important difference for asthma endpoints: an expert consensus report
ανά: Matteo Bonini, κ.ά.
Έκδοση: (2020-06-01)

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders
ανά: Diego Bagnasco, κ.ά.
Έκδοση: (2023-08-01)

Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies
ανά: Giorgio Walter Canonica, κ.ά.
Έκδοση: (2021-09-01)

Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: Evidence from the Severe Asthma Network in Italy (SANI)
ανά: Giorgio Walter Canonica, MD, κ.ά.
Έκδοση: (2025-01-01)

Tezepelumab: patient selection and place in therapy in severe asthma
ανά: Francesco Menzella, κ.ά.
Έκδοση: (2024-04-01)

Treatment strategies for asthma: reshaping the concept of asthma management
ανά: Alberto Papi, κ.ά.
Έκδοση: (2020-08-01)

Omalizumab as add‐on therapy in a patient with severe asthma and OSA
ανά: Giulia Scioscia, κ.ά.
Έκδοση: (2020-03-01)

Efficacy of Mepolizumab in patients with previous Omalizumab treatment failure: real life observation
ανά: Diego Bagnasco, κ.ά.
Έκδοση: (2020-08-01)

The evidence on tiotropium bromide in asthma: from the rationale to the bedside
ανά: Dejan Radovanovic, κ.ά.
Έκδοση: (2017-05-01)

Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
ανά: Corrado Pelaia, κ.ά.
Έκδοση: (2023-03-01)

Vascular remodeling and TSLP/angiogenin overexpression in severe mixed asthma
ανά: Francesca Bertolini, κ.ά.
Έκδοση: (2025-02-01)

Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside
ανά: Dejan Radovanovic, κ.ά.
Έκδοση: (2017-06-01)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
ανά: Erminia Ridolo, κ.ά.
Έκδοση: (2020-10-01)

Brittle asthma
ανά: O. Toungoussova, κ.ά.
Έκδοση: (2016-02-01)

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
ανά: Alessandra Vultaggio, κ.ά.
Έκδοση: (2023-05-01)

Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma–COPD overlap syndrome phenotype
ανά: Lacedonia D, κ.ά.
Έκδοση: (2017-06-01)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
ανά: Giovanna Elisiana Carpagnano, κ.ά.
Έκδοση: (2021-03-01)

SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma
ανά: G. Senna, κ.ά.
Έκδοση: (2017-04-01)

Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis
ανά: Maria D'Amato, κ.ά.
Έκδοση: (2022-05-01)

Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study
ανά: Paolo Solidoro, κ.ά.
Έκδοση: (2019-04-01)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
ανά: Francesco Menzella, κ.ά.
Έκδοση: (2016-12-01)

Positioning tezepelumab for patients with severe asthma: from evidence to unmet needs
ανά: Carlo Lombardi, κ.ά.
Έκδοση: (2024-11-01)

The extracellular matrix of the lung and airway responsiveness in asthma
ανά: F.G. Salerno, κ.ά.
Έκδοση: (2016-01-01)

Alexithymia and asthma: a systematic review
ανά: Orlando Silvestro, κ.ά.
Έκδοση: (2023-08-01)

Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series
ανά: Carlo Lombardi, κ.ά.
Έκδοση: (2024-07-01)

“Characteristics of patients admitted to emergency department for asthma attack: a real-LIFE study”
ανά: Laura Losappio, κ.ά.
Έκδοση: (2019-06-01)

Interleukin-5 in the Pathophysiology of Severe Asthma
ανά: Corrado Pelaia, κ.ά.
Έκδοση: (2019-12-01)

Role of Leukotrienes and Leukotriene Modifiers in Asthma
ανά: Paolo Montuschi
Έκδοση: (2010-06-01)